Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Forecast Data Period | 2026 - 2031 |
| Historical Data Period | 2020 - 2024 |
| Base Year Market Size (2025) | USD 4.71 Million |
| Market Size (2026) | USD 5.09 Million |
| Market Size (2031) | USD 7.52 Million |
| Growth Rate (2026 - 2031) | 8.12% CAGR |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Middle East And Africa Blood Glucose Monitoring Market Analysis by Mordor Intelligence
The Middle East And Africa Blood Glucose Monitoring Market size is expected to grow from USD 4.71 million in 2025 to USD 5.09 million in 2026 and is forecast to reach USD 7.52 million by 2031 at 8.12% CAGR over 2026-2031.
Diabetes and COVID-19 have a significant influence on public health not just overseas but also in the Middle East and Africa. In COVID-19 patients, diabetes has been reported to increase the incidence of both fatal infections and serious infections. Because diabetes is one of the primary health issues that is incredibly prevalent in the Middle East and African countries, the present research focused on understanding the epidemiology of COVID-19 in people with diabetes and the initiatives put in place by the governments to decrease its impact.
There is an increasing incidence of lifestyle diseases, such as diabetes, in developing countries that are increasing the demand for blood glucose monitoring devices. The increased awareness about healthcare facilities and preventive care is also supporting the growth of the market. The number of patients relying on self-monitoring blood glucose (SMBG) has increased. Owing to the high-cost constraints associated with continuous glucose monitoring (CGM), self-monitoring by glucometer is more acceptable in the Middle-East and Africa region. These devices help in the early detection of hypo and hyperglycemia conditions, which tend to drive the market for glucose monitoring.
Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
Middle East And Africa Blood Glucose Monitoring Market Trends and Insights
Test Strips Accounted for The Highest Market Share in Middle East And Africa Blood Glucose Monitoring Devices Market.
In the Middle East and African blood glucose monitoring market, test strips hold 45% of the share with USD 136 million in revenue. Price is often a significant concern when purchasing blood glucose test strips. Although various countries provide reimbursements for prescribed test strips, the majority of patients have to pay for them out of their own pockets. Africa has experienced a rise in the number of diabetic patients over the past decade. Total diabetes-related health expenditure in Africa is nearly USD 9.5 billion and is expected to almost double by 2045.
Governments in the Middle East have seen the threat that diabetes poses and have begun to take action with a number of policies, projects, and programs. In this area, there are still six of the fifteen nations without a national operational action plan for diabetes. Many nations still lack a comprehensive national plan to lower the significant diabetes risk factors of being overweight, obese, and inactive.
National diabetes treatment recommendations have been fully adopted in most areas. Nevertheless, ongoing efforts are being made to reduce diabetes complications. The market will probably continue to rise as a result of the increased incidence of type-2 diabetes, growing genetic risk factors, and the considerations indicated above.
Programs, such as the Base of the Pyramid project, a public-private partnership initiated by Novo Nordisk, aim to increase awareness about diabetes in low- and middle-income countries in Africa. In the Middle East and Africa, due to lifestyle and food habits, blood glucose fluctuations among insulin users are frequent from time to time, and the use of self-monitoring of blood glucose increases. A rise in the diabetic population drives the market by increasing the use of blood glucose monitoring devices.
Obesity is considered one of the major factors contributing to the disease, primarily type-2 diabetes. Also, other factors, such as technological innovations and advancements, provide many conveniences in measuring blood glucose levels. One such advancement in monitoring the blood glucose level is established with continuous glucose monitoring devices. Therefore, due to an increase in the usage of monitoring devices among the type-2 diabetes population, the market is expected to grow.
Saudi Arabia and Iran Together Accounted for over 50% Share in the Middle-East and Africa Blood Glucose Monitoring Devices Market.
Diabetes is one of the mounting health problems the country is facing. Saudi Arabia is ranked among the top three Middle Eastern and African countries with the highest prevalence of diabetes. Saudi Arabia has a 36% market share in the Middle East and Africa for blood glucose monitoring, and Iran is the second-largest market after that.
The high sales of blood glucose monitoring devices in Saudi Arabia are due to the growing prevalence of diabetes in the country. The Middle-East countries have high diabetes prevalence, like Saudi Arabia at 24%, Kuwait at 23%, Bahrain at 22%, Qatar at 20%, and the UAE at approximately 19%. Price is often a significant concern when purchasing blood glucose monitoring devices. Although various countries, like Saudi Arabia, Iran, and other countries in the Middle East and Africa, provide reimbursements for prescribed SMBG devices and their components, most patients have to pay for them out of their pockets.
In recent years, diabetes incidence has increased alarmingly throughout the Middle East and Africa. Because of lifestyle changes, the prevalence of diabetes has reached an all-time high. Numerous health issues are related to diabetes. Diabetes patients must make several daily adjustments to keep their blood glucose levels within acceptable ranges. For example, they may need to take extra insulin or consume more carbs.
Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the Middle East and Africa regions.
Competitive Landscape
The Middle East and Africa blood glucose monitoring market is highly fragmented, with few major manufacturers boasting a global market presence, while the remaining manufacturers are confined to other local or region-specific manufacturers, and local government initiatives encourage the market.
Middle East And Africa Blood Glucose Monitoring Industry Leaders
Medtronic
Dexcom
Johnson & Johnson
F. Hoffmann-La Roche AG
Abbott
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Public-sector diabetes programs and national digital health platforms are becoming clearer entry points for scaling blood glucose monitoring access beyond out-of-pocket purchase, particularly for pediatric Type 1 diabetes and for hospital-led pathways. In June 2026, Egypt launched a presidential initiative under the 100 Million Healthy Lives program to provide CGM devices to 55,000 children living with Type 1 diabetes, underscoring how large tenders and structured care programs can accelerate device and consumables uptake through centralized procurement and follow-up care.
On the technology side, the market is opening up around higher-feature CGM and data services that reduce friction for clinicians and patients, while still leaving space for cost-optimized SMBG where reimbursement is limited and test strips remain the largest revenue pool. Roche Diagnostics Middle East launched the Accu-Chek SmartGuide CGM solution with AI-enabled predictive analytics in Kuwait, Saudi Arabia, and Qatar (January 2026), and regional evidence generation is expanding, such as the July 2026 UAE study using Dexcom G7 in people with Type 2 diabetes. These moves support opportunities for manufacturers and distributors to pair hardware launches with local clinical education, payer dossiers, and integration with country platforms (for example, Saudi Arabia's Sehhaty) to move from standalone devices to monitored pathways in hospitals, clinics, and home care.
Recent Industry Developments
- July 2026: Metabolic, a UAE-based metabolic healthcare provider, collaborated with Dexcom to launch a three-month prospective observational study in the UAE using the Dexcom G7 CGM system for people with Type 2 diabetes. The study focus on real-world clinical impact strengthens local evidence generation, which supports payer and provider adoption discussions for broader CGM use beyond Type 1 diabetes.
- February 2026: Dexcom launched Dexcom Academy in Riyadh as a structured educational program for healthcare professionals focused on best practices in CGM, in collaboration with the Saudi Ministry of Health. Formalizing training and clinical workflows helps reduce adoption friction in hospitals and clinics and supports more standardized CGM utilization across care settings.
- January 2026: Roche Diagnostics Middle East launched the Accu-Chek SmartGuide CGM solution across Kuwait, Saudi Arabia, and Qatar, highlighting AI-enabled predictive capabilities aimed at improving diabetes decision support. The rollout expands competitive intensity in advanced glucose monitoring and pushes differentiation toward software-led features and connected care services alongside sensors and durables.
Research Methodology Framework and Report Scope
Market Definition and Coverage
This methodology includes devices and consumables used to measure blood glucose for diabetes management across the Middle East and Africa, covering self-monitoring solutions and continuous monitoring solutions used in home and clinical settings.
Scope exclusions: We exclude insulin delivery devices, broader diabetes management hardware, and general laboratory chemistry analyzers that are not used for point blood glucose monitoring.
Segmentation Overview
- Device
- Self-monitoring Blood Glucose
- Glucometer Devices
- Test Strips
- Lancets
- Continuous Glucose Monitoring
- Sensors
- Durables
- Self-monitoring Blood Glucose
- End User
- Hospital/Clinics
- Home/Personal
- Geography
- Saudi Arabia
- Iran
- Egypt
- Oman
- South Africa
- Rest of Middle-East and Africa
Data Sources, Market Sizing, and Validation
Desk Research
Desk research was used to build the starting demand context and keep the model tied to observable health and trade signals across the region. We reviewed public health statistics and care pathway references using sources such as the World Health Organization, the International Diabetes Federation, and national health ministry publications across key MEA countries. To anchor the supply side, we checked import and export statistics and tariff line references using UN Comtrade-style series, plus customs-facing guidance where available.
For market structure and pricing, we referenced company annual reports and investor presentations, regulatory notices issued by local authorities, and reputable press coverage to confirm product availability and typical purchasing channels. Where public financial splits were not detailed enough at a regional level, we used a paid subscription covering company financials and business intelligence, and another paid subscription covering patent filings, so assumptions around product mix and technology shifts could be sanity-checked. The desk research sources listed here are illustrative only, and additional public references were used for data collection, cross-checking, and clarification during the study.
Primary Interviews and Surveys
Primary work focused on validating adoption patterns, average selling price ranges, and channel mix for test strips, meters, and CGM components across major MEA hubs and the Rest of MEA. We spoke with a mix of device suppliers, distributors, clinicians, and pharmacy and hospital procurement stakeholders, then used these inputs to confirm what desk research could not fully explain, especially utilization rates and replacement cycles. We captured regional variation through inputs spanning GCC, North Africa, and Sub-Saharan Africa, so no single country overly drove the final totals.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 38% | CXOs: 16% | |
| Mid tier: 43% | Functional/Unit leaders: 26% | |
| Smaller Players: 19% | Managers: 58% |
Market-Sizing & Forecasting
Sizing was built using a top-down demand pool assessment, where diabetes prevalence, treated population share, testing frequency norms, and device replacement cycles were translated into annual unit needs, then priced using country-level and channel-level ASP ranges. We separated expected consumption of test strips and lancets from the installed base and replacement behavior of meters, then layered in CGM adoption using sensor change frequency and durable reuse patterns.
To ensure the totals stayed consistent with market reality, we used selective bottom-up approximations as cross-checks, including distributor channel checks in key countries and sampled ASP times volume ranges by product type, followed by adjustments when the two views did not align. Inputs used in the model included diabetes prevalence trends, diagnosis and treatment rates, share of SMBG versus CGM usage, typical strips per patient per day, CGM sensor wear duration, and observable shifts in reimbursement and tender activity. Forecasting used scenario analysis, where adoption and ASP trajectories were set based on expert consensus and then stress-tested for affordability and access constraints. When a country-level data point was missing, we applied proxies using population structure and healthcare access indicators, and re-checked those assumptions with regional respondents before retaining them.
Data Validation & Update Cycle
Outputs were validated through consistency checks across demand logic, price bands, and implied per-patient spending, then compared against independent signals such as trade movements and public procurement direction. Any sharp swings by country or product type were reviewed again, and follow-up calls were triggered when variance could not be explained by a clear policy, pricing, or adoption change.
Before sign-off, the work goes through a multi-step internal review to ensure assumptions, units, and currency conversions are consistent across the model. Reports are refreshed annually, with interim updates when a material event occurs, for example a reimbursement shift or a major tender cycle. Right before delivery, a final pass is performed to confirm the latest public indicators and verified inputs are reflected in the numbers.
Mordor Intelligence's Middle East and Africa Blood Glucose Monitoring Market Market Size Compared Against Other Published Estimates
Published market sizes for blood glucose monitoring in the Middle East and Africa often do not match because the scope boundary can move, and some publications count the same device as part of a broader diabetes device basket. Differences also stem from how pricing is treated across public and private channels, how quickly CGM adoption is assumed to rise, and whether sizing is tied to patient testing behavior or supplier revenue allocation.
The biggest gap drivers are whether the number includes only monitoring devices and their consumables, or also insulin delivery and other diabetes care equipment, which pushes totals higher. Another frequent driver is the year and currency approach, where some studies use different base years or apply aggressive ASP increases without reconciling them with tender pricing and affordability constraints. The gap widens further if the update cadence lags fast policy and coverage changes.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Mordor Intelligence | USD 4.71 M (2025) | |
| Regional Consultancy A | USD 1.50 B (2024) | Uses a wider definition of glucose monitoring devices that appears to bundle monitoring with adjacent diabetes device categories, and the pricing base looks closer to high-income private channel averages than blended regional pricing. |
| Trade Journal B | USD 4.34 M (2024) | Anchors the current value one year earlier and appears to rely more on historical reporting with fewer explicit checks on CGM uptake pace and replenishment frequency assumptions across MEA countries. |
The table shows a very wide spread, and in Mordor Intelligence's model the total is limited to glucose monitoring methods (SMBG and CGM) and their direct consumables, rather than a larger diabetes care devices basket. Once the scope is held steady and the unit logic is traced to testing frequency, sensor change cadence, and realistic channel pricing, the remaining differences mostly come down to base-year choice and how quickly adoption is assumed to accelerate.
Key Questions Answered in the Report
How big is the Middle East And Africa Blood Glucose Monitoring Market?
The Middle East And Africa Blood Glucose Monitoring Market size is expected to reach USD 5.09 million in 2026 and grow at a CAGR of 8.12% to reach USD 7.52 million by 2031.
What is the current Middle East And Africa Blood Glucose Monitoring Market size?
In 2026, the Middle East And Africa Blood Glucose Monitoring Market size is expected to reach USD 5.09 million.
Who are the key players in Middle East And Africa Blood Glucose Monitoring Market?
Medtronic, Dexcom, Johnson & Johnson, F. Hoffmann-La Roche AG and Abbott are the major companies operating in the Middle East And Africa Blood Glucose Monitoring Market.
What years does this Middle East And Africa Blood Glucose Monitoring Market cover, and what was the market size in 2025?
In 2025, the Middle East And Africa Blood Glucose Monitoring Market size was estimated at USD 5.09 million. The report covers the Middle East And Africa Blood Glucose Monitoring Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Middle East And Africa Blood Glucose Monitoring Market size for years: 2026, 2027, 2028, 2029, 2030 and 2031.
Page last updated on:
